EQ Stock Summary and Trading Ideas (Equillium | NASDAQ:EQ)

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Equillium trades on the NASDAQ stock market under the symbol EQ.

As of November 10, 2026, EQ stock price declined to $1.46 with 38,766 million shares trading.

EQ has a beta of 0.46, meaning it tends to be less sensitive to market movements. EQ has a correlation of 0.00 to the broad based SPY ETF.

EQ has a market cap of $114.41 million. This is considered a Micro Cap stock.

In the last 3 years, EQ traded as high as $3.54 and as low as $.27.

The top ETF exchange traded funds that EQ belongs to (by Net Assets): VTI, VXF, IWC, AVSC, QQQS.

EQ has outperformed the market in the last year with a price return of +32.7% while the SPY ETF gained +12.3%. However, in the short term, EQ had mixed performance relative to the market. It has underperformed in the last 3 months, returning -30.8% vs -3.3% return in SPY. But in the last 2 weeks, EQ shares have fared better than the market returning +16.8% compared to SPY -2.5%.

EQ support price is $1.38 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EQ shares will trade within this expected range on the day.